![Immunohistochemistry-Paraffin: Kappa Light Chain Antibody (H16-E) [NBP1-30140] - Human tissue (4 um section) stained with anti - Human Kappa light chain (DB 038) monospecific clonal antibody.](http://images.novusbio.com/fullsize/Kappa-Light-Chain-Antibody-H16-E-Immunohistochemistry-Paraffin-NBP1-30140-img0003.jpg "Immunohistochemistry-Paraffin: Kappa Light Chain Antibody (H16-E) [NBP1-30140] - Human tissue (4 um section) stained with anti - Human Kappa light chain (DB 038) monospecific clonal antibody.")
| Reactivity | HuSpecies Glossary |
| Applications | IHC |
| Clone | H16-E |
| Clonality | Monoclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Description | This antibody is immunoaffinity purified with immunogenic peptide as a ligand. |
| Immunogen | Peptide derived from C-terminal sequence of human kappa light chain IgG. Antibody recognizes the epitope between Gly92 - Gly104. |
| Epitope | Gly92 - Gly104 |
| Specificity | This antibody is specific to the C terminus of Human IGKC |
| Isotype | IgG |
| Clonality | Monoclonal |
| Host | Rabbit |
| Gene | IGKC |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Publications |
|
| Storage | Store at 4C. Do not freeze. |
| Buffer | 20mM Tris-HCl (pH 8.0) and 20mg/ml BSA |
| Preservative | 0.05% Sodium Azide |
| Purity | Immunogen affinity purified |
| Publication using NBP1-30140 | Applications | Species |
|---|---|---|
| Wt, Takeuchi E, Oka S et al. Localized primary amyloidosis of the breast: a case report and review of the literature. BMC Surgery 2016-09-13 [PMID: 27624800] |
Secondary Antibodies |
Isotype Controls |
Research Areas for Kappa Light Chain Antibody (NBP1-30140)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![Control Mouse IgG3 Isotype Control (133316) [Unconjugated]](https://images.novusbio.com/images2/IgG3_MAB007_Control_19774.jpg)
![Immunohistochemistry CCR2 Antibody (48607) [Unconjugated]](https://images.novusbio.com/images2/CCR2_MAB150_Immunohistochemistry_18879.jpg)
![Flow Cytometry CCR2 Antibody (48607) [Unconjugated]](https://images.novusbio.com/images2/CCR2_MAB150_Flow_Cytometry_19981.jpg)
![Flow Cytometry CCR2 Antibody (48607) [Unconjugated]](https://images.novusbio.com/images/mab150_human-ccr2-mab-clone-48607-flow-cytometry-121220255522717.jpg)
![N/A CXCL9/MIG [HRP]](https://images.novusbio.com/images2/CXCL9_DCX900_ELISA_75.jpg)
![N/A CXCL9/MIG [HRP]](https://images.novusbio.com/images2/DATA_CXCL9_DCX900_ELISA_646.jpg)
![N/A CXCL9/MIG [HRP]](https://images.novusbio.com/images2/DATA_CXCL9_DCX900_ELISA_647.jpg)
![Immunocytochemistry Progesterone R/NR3C3 Antibody [Unconjugated]](https://images.novusbio.com/images2/Progesterone_R_AF5415_Immunocytochemistry__Immunofluorescence_20674.jpg)
![Immunohistochemistry Progesterone R/NR3C3 Antibody [Unconjugated]](https://images.novusbio.com/images2/Progesterone_R_AF5415_Immunohistochemistry_20779.jpg)
![Western Blot Progesterone R/NR3C3 Antibody [Unconjugated]](https://images.novusbio.com/images2/Progesterone_R_AF5415_Western_Blot_5715.jpg)
![SDS-PAGE TGF-beta 2 [Unconjugated]](https://images.novusbio.com/images2/TGF-beta_2_302-B2_268.jpg)
![Bioactivity TGF-beta 2 [Unconjugated]](https://images.novusbio.com/images2/TGF-beta_2_302-B2_269.jpg)
![Surface Plasmon Resonance (SPR) TGF-beta 2 [Unconjugated]](https://images.novusbio.com/images/302-b2_recombinant-human-tgf-beta-2-protein-surface-plasmon-resonance-spr-144202585019..jpg)
![Bioactivity TGF-beta 3 [Unconjugated]](https://images.novusbio.com/images/243-b3_recombinant-human-tgf-beta-3-protein-bioactivity-1342023172157.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")